nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.407	1	CbGbCtD
Zalcitabine—SLC22A7—Organic anion transport—SLC22A12—nephrolithiasis	0.0316	0.121	CbGpPWpGaD
Zalcitabine—Oral lesion—Hydrochlorothiazide—nephrolithiasis	0.0226	0.0845	CcSEcCtD
Zalcitabine—SLC22A6—Organic anion transport—SLC22A12—nephrolithiasis	0.0221	0.0845	CbGpPWpGaD
Zalcitabine—DCK—Purine salvage—APRT—nephrolithiasis	0.0202	0.077	CbGpPWpGaD
Zalcitabine—SLC22A7—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0147	0.0561	CbGpPWpGaD
Zalcitabine—Oral disorder—Hydrochlorothiazide—nephrolithiasis	0.013	0.0486	CcSEcCtD
Zalcitabine—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0103	0.0394	CbGpPWpGaD
Zalcitabine—DCK—Purine metabolism—APRT—nephrolithiasis	0.00958	0.0366	CbGpPWpGaD
Zalcitabine—Epigastric pain—Hydrochlorothiazide—nephrolithiasis	0.0068	0.0254	CcSEcCtD
Zalcitabine—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.0067	0.025	CcSEcCtD
Zalcitabine—CYP2C9—urine—nephrolithiasis	0.00574	0.0902	CbGeAlD
Zalcitabine—Toothache—Hydrochlorothiazide—nephrolithiasis	0.0054	0.0202	CcSEcCtD
Zalcitabine—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.00517	0.0193	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00489	0.0187	CbGpPWpGaD
Zalcitabine—DCK—Nucleotide metabolism—APRT—nephrolithiasis	0.00481	0.0184	CbGpPWpGaD
Zalcitabine—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.00478	0.0178	CcSEcCtD
Zalcitabine—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00456	0.017	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00447	0.0171	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00447	0.0171	CbGpPWpGaD
Zalcitabine—CYP3A4—urine—nephrolithiasis	0.00438	0.0688	CbGeAlD
Zalcitabine—CYP2D6—urine—nephrolithiasis	0.00431	0.0677	CbGeAlD
Zalcitabine—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00406	0.0151	CcSEcCtD
Zalcitabine—SLC22A6—nephron tubule—nephrolithiasis	0.00397	0.0624	CbGeAlD
Zalcitabine—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.00379	0.0596	CbGeAlD
Zalcitabine—SLC22A7—renal system—nephrolithiasis	0.00374	0.0588	CbGeAlD
Zalcitabine—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00366	0.0137	CcSEcCtD
Zalcitabine—SLC22A7—kidney—nephrolithiasis	0.00361	0.0568	CbGeAlD
Zalcitabine—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00354	0.0132	CcSEcCtD
Zalcitabine—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00354	0.0132	CcSEcCtD
Zalcitabine—SLC22A7—cortex of kidney—nephrolithiasis	0.00352	0.0553	CbGeAlD
Zalcitabine—Gout—Hydrochlorothiazide—nephrolithiasis	0.00352	0.0131	CcSEcCtD
Zalcitabine—SLC22A6—cortex of kidney—nephrolithiasis	0.0034	0.0534	CbGeAlD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00339	0.0129	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00339	0.0129	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00339	0.0129	CbGpPWpGaD
Zalcitabine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00335	0.0125	CcSEcCtD
Zalcitabine—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00335	0.0125	CcSEcCtD
Zalcitabine—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.00325	0.051	CbGeAlD
Zalcitabine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00323	0.0121	CcSEcCtD
Zalcitabine—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00319	0.0119	CcSEcCtD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00315	0.012	CbGpPWpGaD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00315	0.012	CbGpPWpGaD
Zalcitabine—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0031	0.0116	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0031	0.0118	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0031	0.0118	CbGpPWpGaD
Zalcitabine—DCK—nephron tubule—nephrolithiasis	0.00303	0.0476	CbGeAlD
Zalcitabine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.003	0.0112	CcSEcCtD
Zalcitabine—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00297	0.0111	CcSEcCtD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00294	0.0112	CbGpPWpGaD
Zalcitabine—SLC29A1—renal system—nephrolithiasis	0.00289	0.0453	CbGeAlD
Zalcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00281	0.0107	CbGpPWpGaD
Zalcitabine—SLC29A1—kidney—nephrolithiasis	0.00279	0.0438	CbGeAlD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00279	0.0106	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00279	0.0106	CbGpPWpGaD
Zalcitabine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00274	0.0102	CcSEcCtD
Zalcitabine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00274	0.0105	CbGpPWpGaD
Zalcitabine—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00272	0.0101	CcSEcCtD
Zalcitabine—SLC29A1—cortex of kidney—nephrolithiasis	0.00272	0.0427	CbGeAlD
Zalcitabine—Swelling—Hydrochlorothiazide—nephrolithiasis	0.0027	0.0101	CcSEcCtD
Zalcitabine—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00995	CcSEcCtD
Zalcitabine—DCK—cortex of kidney—nephrolithiasis	0.0026	0.0408	CbGeAlD
Zalcitabine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00257	0.0096	CcSEcCtD
Zalcitabine—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00952	CcSEcCtD
Zalcitabine—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00944	CcSEcCtD
Zalcitabine—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00944	CcSEcCtD
Zalcitabine—CYP3A43—Biological oxidations—SLC26A1—nephrolithiasis	0.00252	0.00961	CbGpPWpGaD
Zalcitabine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00252	0.0094	CcSEcCtD
Zalcitabine—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00936	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00248	0.00948	CbGpPWpGaD
Zalcitabine—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00924	CcSEcCtD
Zalcitabine—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00916	CcSEcCtD
Zalcitabine—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00894	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00239	0.0089	CcSEcCtD
Zalcitabine—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00239	0.0089	CcSEcCtD
Zalcitabine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00237	0.00883	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00235	0.00896	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00235	0.00896	CbGpPWpGaD
Zalcitabine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00235	0.00876	CcSEcCtD
Zalcitabine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00235	0.00876	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00227	0.00867	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00227	0.00867	CbGpPWpGaD
Zalcitabine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00843	CcSEcCtD
Zalcitabine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00837	CcSEcCtD
Zalcitabine—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00223	0.00834	CcSEcCtD
Zalcitabine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00816	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00218	0.00833	CbGpPWpGaD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00218	0.00833	CbGpPWpGaD
Zalcitabine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00218	0.00813	CcSEcCtD
Zalcitabine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00217	0.0081	CcSEcCtD
Zalcitabine—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00802	CcSEcCtD
Zalcitabine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00788	CcSEcCtD
Zalcitabine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00785	CcSEcCtD
Zalcitabine—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00775	CcSEcCtD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00207	0.00789	CbGpPWpGaD
Zalcitabine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00206	0.0077	CcSEcCtD
Zalcitabine—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00754	CcSEcCtD
Zalcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00195	0.00743	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00193	0.00737	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00193	0.00737	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00193	0.00737	CbGpPWpGaD
Zalcitabine—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00193	0.0072	CcSEcCtD
Zalcitabine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00193	0.0072	CcSEcCtD
Zalcitabine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00192	0.00733	CbGpPWpGaD
Zalcitabine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00711	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00702	CcSEcCtD
Zalcitabine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00186	0.00694	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0018	0.00673	CcSEcCtD
Zalcitabine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00669	CcSEcCtD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00177	0.00674	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00177	0.00674	CbGpPWpGaD
Zalcitabine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00647	CcSEcCtD
Zalcitabine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00172	0.00644	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00172	0.00657	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00172	0.00657	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00172	0.00657	CbGpPWpGaD
Zalcitabine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00617	CcSEcCtD
Zalcitabine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00616	CcSEcCtD
Zalcitabine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00164	0.00611	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.0016	0.00611	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.0016	0.00611	CbGpPWpGaD
Zalcitabine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00159	0.00594	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00157	0.00601	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00157	0.00601	CbGpPWpGaD
Zalcitabine—CYP3A5—nephron tubule—nephrolithiasis	0.00157	0.0247	CbGeAlD
Zalcitabine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00574	CcSEcCtD
Zalcitabine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00153	0.00572	CcSEcCtD
Zalcitabine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00147	0.0055	CcSEcCtD
Zalcitabine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00146	0.00544	CcSEcCtD
Zalcitabine—CYP3A5—renal system—nephrolithiasis	0.00143	0.0224	CbGeAlD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00143	0.00545	CbGpPWpGaD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00143	0.00545	CbGpPWpGaD
Zalcitabine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00142	0.00528	CcSEcCtD
Zalcitabine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00526	CcSEcCtD
Zalcitabine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00525	CcSEcCtD
Zalcitabine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00521	CcSEcCtD
Zalcitabine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00139	0.00519	CcSEcCtD
Zalcitabine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00138	0.00515	CcSEcCtD
Zalcitabine—CYP3A5—kidney—nephrolithiasis	0.00138	0.0217	CbGeAlD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00135	0.00517	CbGpPWpGaD
Zalcitabine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00135	0.00505	CcSEcCtD
Zalcitabine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00135	0.00502	CcSEcCtD
Zalcitabine—CYP3A5—cortex of kidney—nephrolithiasis	0.00134	0.0211	CbGeAlD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00134	0.00511	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00134	0.00511	CbGpPWpGaD
Zalcitabine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00133	0.00497	CcSEcCtD
Zalcitabine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00133	0.00496	CcSEcCtD
Zalcitabine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00493	CcSEcCtD
Zalcitabine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.0013	0.00484	CcSEcCtD
Zalcitabine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00129	0.00482	CcSEcCtD
Zalcitabine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00129	0.00481	CcSEcCtD
Zalcitabine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00129	0.0048	CcSEcCtD
Zalcitabine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00127	0.00474	CcSEcCtD
Zalcitabine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00126	0.00471	CcSEcCtD
Zalcitabine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00468	CcSEcCtD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00124	0.00475	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00124	0.00475	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00124	0.00473	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00124	0.00473	CbGpPWpGaD
Zalcitabine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00456	CcSEcCtD
Zalcitabine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00456	CcSEcCtD
Zalcitabine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00455	CcSEcCtD
Zalcitabine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00451	CcSEcCtD
Zalcitabine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0012	0.00446	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00119	0.00456	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00119	0.00456	CbGpPWpGaD
Zalcitabine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00441	CcSEcCtD
Zalcitabine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00117	0.00438	CcSEcCtD
Zalcitabine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00431	CcSEcCtD
Zalcitabine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00428	CcSEcCtD
Zalcitabine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00427	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00114	0.00435	CbGpPWpGaD
Zalcitabine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00423	CcSEcCtD
Zalcitabine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00417	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00111	0.00424	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00111	0.00424	CbGpPWpGaD
Zalcitabine—SLC22A7—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00111	0.00423	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0011	0.0042	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0011	0.0042	CbGpPWpGaD
Zalcitabine—CYP3A4—renal system—nephrolithiasis	0.00107	0.0168	CbGeAlD
Zalcitabine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00399	CcSEcCtD
Zalcitabine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00106	0.00396	CcSEcCtD
Zalcitabine—CYP2D6—renal system—nephrolithiasis	0.00105	0.0166	CbGeAlD
Zalcitabine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00105	0.0039	CcSEcCtD
Zalcitabine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00389	CcSEcCtD
Zalcitabine—CYP3A4—kidney—nephrolithiasis	0.00104	0.0163	CbGeAlD
Zalcitabine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00103	0.00385	CcSEcCtD
Zalcitabine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00102	0.0038	CcSEcCtD
Zalcitabine—CYP2D6—kidney—nephrolithiasis	0.00102	0.016	CbGeAlD
Zalcitabine—CYP3A7—Biological oxidations—SLC26A1—nephrolithiasis	0.00101	0.00387	CbGpPWpGaD
Zalcitabine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00101	0.00377	CcSEcCtD
Zalcitabine—Pain—Hydrochlorothiazide—nephrolithiasis	0.001	0.00374	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000989	0.00377	CbGpPWpGaD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000989	0.00377	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000981	0.00375	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000966	0.00361	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000959	0.00358	CcSEcCtD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000939	0.00358	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000939	0.00358	CbGpPWpGaD
Zalcitabine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000931	0.00348	CcSEcCtD
Zalcitabine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000927	0.00346	CcSEcCtD
Zalcitabine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000927	0.00346	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000897	0.00343	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000897	0.00343	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000873	0.00333	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000873	0.00333	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000864	0.00322	CcSEcCtD
Zalcitabine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000841	0.00314	CcSEcCtD
Zalcitabine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00083	0.0031	CcSEcCtD
Zalcitabine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000802	0.00299	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00079	0.00302	CbGpPWpGaD
Zalcitabine—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000778	0.00297	CbGpPWpGaD
Zalcitabine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000775	0.00289	CcSEcCtD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000772	0.00295	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000772	0.00295	CbGpPWpGaD
Zalcitabine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000745	0.00278	CcSEcCtD
Zalcitabine—Rash—Hydrochlorothiazide—nephrolithiasis	0.000739	0.00276	CcSEcCtD
Zalcitabine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000739	0.00276	CcSEcCtD
Zalcitabine—Headache—Hydrochlorothiazide—nephrolithiasis	0.000735	0.00274	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.000733	0.0028	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000688	0.00263	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00068	0.0026	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00068	0.0026	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000632	0.00241	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000632	0.00241	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000629	0.0024	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000629	0.0024	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GRHPR—nephrolithiasis	0.000577	0.0022	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GRHPR—nephrolithiasis	0.000568	0.00217	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000563	0.00215	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000563	0.00215	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000521	0.00199	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000517	0.00197	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AGXT—nephrolithiasis	0.000514	0.00196	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AGXT—nephrolithiasis	0.000506	0.00193	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000477	0.00182	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000477	0.00182	CbGpPWpGaD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00045	0.00172	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000443	0.00169	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000443	0.00169	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—SLC26A1—nephrolithiasis	0.000437	0.00167	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—APRT—nephrolithiasis	0.000437	0.00167	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—APRT—nephrolithiasis	0.000431	0.00164	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—SLC26A1—nephrolithiasis	0.000431	0.00164	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000395	0.00151	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000395	0.00151	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000341	0.0013	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000316	0.00121	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AQP1—nephrolithiasis	0.000311	0.00119	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AQP1—nephrolithiasis	0.000307	0.00117	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CHRM3—nephrolithiasis	0.000282	0.00108	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CHRM3—nephrolithiasis	0.000277	0.00106	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GRHPR—nephrolithiasis	0.000229	0.000874	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AGXT—nephrolithiasis	0.000204	0.000779	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—SLC26A1—nephrolithiasis	0.000173	0.000662	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—APRT—nephrolithiasis	0.000173	0.000662	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GRHPR—nephrolithiasis	0.000165	0.000631	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AGXT—nephrolithiasis	0.000147	0.000563	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—APRT—nephrolithiasis	0.000125	0.000479	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	0.000125	0.000479	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AQP1—nephrolithiasis	0.000124	0.000472	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000118	0.000449	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000117	0.000445	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CHRM3—nephrolithiasis	0.000112	0.000427	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000105	0.0004	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000104	0.000397	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AQP1—nephrolithiasis	8.93e-05	0.000341	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—APRT—nephrolithiasis	8.91e-05	0.00034	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	8.91e-05	0.00034	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	8.84e-05	0.000337	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—APRT—nephrolithiasis	8.84e-05	0.000337	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CHRM3—nephrolithiasis	8.08e-05	0.000308	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	7.69e-05	0.000294	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AGXT—nephrolithiasis	6.85e-05	0.000262	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AQP1—nephrolithiasis	6.35e-05	0.000242	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AQP1—nephrolithiasis	6.3e-05	0.00024	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—APRT—nephrolithiasis	5.83e-05	0.000222	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	5.83e-05	0.000222	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	5.74e-05	0.000219	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CHRM3—nephrolithiasis	5.69e-05	0.000217	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AQP1—nephrolithiasis	4.15e-05	0.000159	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	3.76e-05	0.000143	CbGpPWpGaD
